<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555123</url>
  </required_header>
  <id_info>
    <org_study_id>YY_YYBRS001</org_study_id>
    <nct_id>NCT03555123</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Parallel, Placebo-controlled Study l to Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX in Patients With Acutely Decompensated Heart Failure : Korea Bridging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, Multicenter, parallel, placebo-controlled study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous
      infusion of Levosimendan for 24hrs in patients with ADHF who will be hospitalized with ADHF
      and continue to have symptom of dyspnea at rest(NYHA Class III or IV) despite with treatment
      of SOCs(include intravenous diuretics, vasodilators and/or positive inotropic drugs but
      except amrinone and milrinone) within 48hrs

      Efficacy is measured by Clinical composite classification(Improved, No change, Worse),
      bio-marker(change of BNP and ST-2), Patient's Global Assessment, NYHA functional
      Classification, hospitalization period and renal function tests(change of creatinine, BUN and
      NGAL) Safety is measured by recording the incidence of adverse events(AEs), vital signs,
      clinical blood safety tests(biochemistry, hematology) and concomitant medications
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 30, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the Clinical Composite Classification(CCC)</measure>
    <time_frame>5day</time_frame>
    <description>Assessment of the Clinical Composite Classification(CCC) using the Patients Global Assessment(PGA) at 5day after start of IV levosiemendan or Placebo infusion with WHF through 5dyas: Improved, Unchanged, Worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BNP</measure>
    <time_frame>baseline to 24hr, 48hr, 72hr, and 5day</time_frame>
    <description>Change from baseline in plasma BNP levels at 24hr, 48hr, 72hr, and 5day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST2</measure>
    <time_frame>baseline to 24hr, 48hr, 72hr, and 5day</time_frame>
    <description>Change from baseline in plasma ST2 at 24hr, 48hr, 72hr, 5day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA</measure>
    <time_frame>baseline to 5day</time_frame>
    <description>New York Heart Association(NYHA) functional classification at 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization</measure>
    <time_frame>31day</time_frame>
    <description>Length of intensive care unit and /or Coronary care unit stay for the index ADHF hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardio-renal biomarkers</measure>
    <time_frame>baseline to 24hr, 48hr, 72hr, and 5day</time_frame>
    <description>Change from baseline in cardio-renal biomarkers (Creatinine, BUN, NGAL) at 24hr, 48hr, 72hr and 5day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment</measure>
    <time_frame>6hr</time_frame>
    <description>Patient's Global Assessment (PGA, 7-likert scale) at 6 hr.
: Check rate of patients who responded with Moderate or Marked improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Assessment</measure>
    <time_frame>6hr</time_frame>
    <description>Patients Assessment of dyspnea(7-likert scale) at 6hr
: Check rate of patients who responded with Moderate or Marked improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-hospitalization</measure>
    <time_frame>30days</time_frame>
    <description>Time to re-hospitalization due to heart failure after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death.</measure>
    <time_frame>30days</time_frame>
    <description>Time to CV death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30days</time_frame>
    <description>All cause mortality through 30days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>SIMDAX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levosimendan2.5mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIMDAX Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water for injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simdax</intervention_name>
    <description>Levosimendan2.5mg/ml</description>
    <arm_group_label>SIMDAX</arm_group_label>
    <arm_group_label>SIMDAX Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written, signed and dated informed consent by the patient or the patient's legally
             authorized representative.

          2. Male and female patients over 18 years of age.

          3. Patients with chronic heart failure who were diagnosed with acute decompensated heart
             failure

          4. Hospitalization for with a primary or secondary diagnosis at admission of worsening
             heart failure within the 48 hours prior to start of study drug infusion. Symptoms of
             worsening heart failure must have been treated with IV diuretics Patients who have
             been hospitalized more than 48 hours may be enrolled if they fail to improve
             clinically to treatments administered during the first 48 hours (1)(following initial
             improvement) their clinical status deteriorates either spontaneously or following the
             withdrawal of intravenous medications.

        (2) Infusion rates for continuous IV diuretics, inotropes and vasodilators must have been
        unchanged for at least 2 hours prior to baseline.

        5.Left ventricular ejection fraction less than or equal to 35% as assessed using
        echocardiography, radionuclide ventriculography or contrast angiography within the previous
        12 months 6.Dyspnea at rest at both screening and baseline, as assessed by the patient.

        Exclusion Criteria:

          1. Severe obstruction of ventricular outflow tracts such as hemodynamically significant
             uncorrected primary valve disease and restrictive or hypertrophic cardiomyopathy.

          2. Patients scheduled to receive angioplasty, cardiac surgery, a LV assist device or a
             heart transplant within 3months after randomization.

          3. Patients who have undergone cardioversion during the 4 hours prior to baseline or are
             expected to undergo cardioversion in the 5 days after baseline.

          4. Patients who have undergone a cardiac resynchronization procedure within the 30 days
             of screening or are expected to undergo such a procedure within 3 months.

          5. Patients who have received an IV diuretics dose (including or change in dose of a
             continuous diuretic infusion) within 2 hours of the baseline assessments.

          6. Patients who are intubated or otherwise not able to comply with the pre-study
             assessments.

          7. Stroke or TIA within 3 months prior to randomization.

          8. Systolic blood pressure 90 mmHg or less at screening or baseline.

          9. Heart rate 120 bpm or greater, persistent for at least 5 minutes at screening or
             baseline.

         10. Serum potassium less than 3.5mmol/l or greater than 5.4 mmol/l.

         11. Angina pectoris during the 6 hours before baseline.

         12. Administration of amrinone or milrinone within 24 hours before start of study drug
             infusion.

         13. Hypersensitivity to levosimendan or any of the excipients: Povidone, Citric acid,
             Ethanol

         14. A history of Torsades de Pointes.

         15. Severe renal insufficiency (serum creatinine &gt; 450mol/l (5.0 mg/dl)) or on dialysis.

         16. Significant hepatic impairment or elevation of liver enzymes to 5 times the upper
             limit of normal.

         17. Acute bleeding or severe anemia (hemoglobin &lt; 10g/dl or blood transfusion during
             current admission) or acute decompensation due to an active infection

         18. Patients with low hemoglobin between 9-10g/dl may be

         19. Enrolled provided there is no evidence of bleeding, no intention to transfuse blood,
             no identified cause for anemia other than renal insufficiency and if the severity of
             anemia is longstanding (documented hemoglobin +/-1 g/dl of screening value &gt; 30 days
             prior).

         20. History of severe chronic obstructive pulmonary disease or unstable bronchial asthma
             as evidenced by e.g. CO2 retention or ongoing use of oral, intravenous or
             intramuscular steroids

         21. Patients with pneumonia or pneumothorax

         22. Patients with non-cardiac respiratory distress

         23. A person with a BNP level of less than 100pg/mL on screening for an organ laboratory
             test.

         24. Active infected patients who need to have symptoms of fever over 38.5â„ƒ or get an
             intravenous administration of septicemia or antimicrobial agents.

         25. Pregnant and lactating women

         26. Patients who take Investigational Product including other clinical study within
             screening 4 weeks.

         27. In case of unsuitable patients who are participated in this study because of other
             reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kang Suck-min</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwon Min-kyung</last_name>
    <phone>+82-2-6202-7104</phone>
    <email>mkkwon@yypharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Su-min</last_name>
    <phone>+82-2-6202-7119</phone>
    <email>smlee@yypharm.co.kr</email>
  </overall_contact_backup>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

